10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Quest Partners LLC

Quest Partners LLC reduced its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 20.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,593 shares of the company’s stock after selling 3,421 shares during the period. Quest Partners LLC’s holdings in 10x Genomics were worth $307,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. ARK Investment Management LLC grew its holdings in 10x Genomics by 15.4% in the third quarter. ARK Investment Management LLC now owns 10,750,345 shares of the company’s stock valued at $242,743,000 after purchasing an additional 1,436,582 shares during the period. Vanguard Group Inc. grew its holdings in 10x Genomics by 1.0% in the first quarter. Vanguard Group Inc. now owns 9,101,536 shares of the company’s stock valued at $341,581,000 after purchasing an additional 90,204 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its holdings in 10x Genomics by 3.7% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,373,212 shares of the company’s stock valued at $143,907,000 after purchasing an additional 230,145 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of 10x Genomics by 69.6% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 6,143,067 shares of the company’s stock worth $119,483,000 after acquiring an additional 2,521,289 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of 10x Genomics by 17.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,657,227 shares of the company’s stock worth $137,257,000 after acquiring an additional 553,053 shares during the last quarter. 84.68% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on TXG shares. UBS Group lowered their price target on 10x Genomics from $25.00 to $20.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 30th. Morgan Stanley lowered their price target on 10x Genomics from $50.00 to $46.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. JPMorgan Chase & Co. lowered their price target on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 30th. Leerink Partnrs raised 10x Genomics to a “strong-buy” rating in a research note on Tuesday, September 3rd. Finally, Citigroup lowered their price target on 10x Genomics from $35.00 to $23.00 and set a “buy” rating on the stock in a research note on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $29.19.

10x Genomics Stock Up 6.9 %

Shares of 10x Genomics stock opened at $15.30 on Tuesday. The firm has a market cap of $1.85 billion, a PE ratio of -10.00 and a beta of 1.87. 10x Genomics, Inc. has a 52 week low of $12.95 and a 52 week high of $57.90. The business’s fifty day simple moving average is $17.44 and its 200-day simple moving average is $19.81.

10x Genomics (NASDAQ:TXG) last posted its earnings results on Tuesday, October 29th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.04. The company had revenue of $151.65 million for the quarter, compared to analysts’ expectations of $158.84 million. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. 10x Genomics’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.51) earnings per share. As a group, equities analysts expect that 10x Genomics, Inc. will post -1.4 earnings per share for the current year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.